Atherosclerosis Treatment with Stimuli‐Responsive Nanoagents: Recent Advances and Future Perspectives

Maruf, Ali; Wang, Yi; Yin, Tieyin; Huang, Junli; Wang, Nan; Durkan, Colm; Tan, Youhua; Wu, Wei; Wang, Guixue

doi:10.1002/adhm.201900036

Cited by 67 publications

(46 citation statements)

References 246 publications

(289 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In advanced atherosclerotic lesions, intracellular and extracellular ROS levels increased, [ 6 ] thus opening big opportunities to develop intelligent drug delivery systems that are responsive toward a biologically relevant environment of inflamed blood vessels for enhancing drug delivery. [ 7–9 ]…”

Section: Introductionmentioning

confidence: 99%

Nanoerythrocyte Membrane–Enveloped ROS‐Responsive 5‐Aminolevulinic Acid Prodrug Nanostructures with Robust Atheroprotection

Maruf

Wang

Luo

et al. 2020

Part & Part Syst Charact

Self Cite

View full text Add to dashboard Cite

The development of smart nanoagents that can respond to a specific stimulus has gained remarkable interest for treating various kinds of diseases, including atherosclerosis. On the other hand, a cell camouflaging strategy has been considered as a pivotal factor to improve the delivery stealthiness, biocompatibility, and biodegradability of nanocarriers, resolving the shortcomings of PEGylation. In this study, reactive oxygen species (ROS)‐responsive 5‐aminolevulinic acid (ALA) prodrug nanostructures (ROSELLA) encapsulating rapamycin (RAP) are blended with nanoerythrocyte membranes to construct red blood cell membrane (RBCM)/RAP@ROSELLA. These nanoagents are designed to be able to escape the biological barriers, accumulate in atherosclerosis lesions, and enhance the release of drugs in the intracellular milieu due to the magnification of hydrogen peroxide (H2O2). In vitro study proves its superior ability to inhibit the proliferation of macrophages and vascular smooth muscle cells. In vivo developmental toxicity further confirms that no significant systematic toxicity is induced by RBCM/RAP@ROSELLA, implying its favorable biocompatibility, which has potential for precise nanomedicine to combat atherosclerosis.

show abstract

Section: Introductionmentioning

confidence: 99%

Nanoerythrocyte Membrane–Enveloped ROS‐Responsive 5‐Aminolevulinic Acid Prodrug Nanostructures with Robust Atheroprotection

Maruf

Wang

Luo

et al. 2020

Part & Part Syst Charact

Self Cite

View full text Add to dashboard Cite

show abstract

“…As shown in Moreover, PC SV showed a relatively constant hydrodynamic diameter after long-term storage at room temperature, indicating its favorable stability properties (Fig.S3). This good stability of nano-carrier in physiological condition was important and bene cial for their in vivo application and intravenous injection [17][18][19] . In addition, surface zeta potential analysis showed that BPC had a zeta potential of − 20.8 ± 0.8 mV, whereas PC S (− 25.4 ± 1.5 mV) and PC SV (− 38.8 ± 1.7 mV) have lower values ( Fig.…”

Section: Resultsmentioning

confidence: 99%

A PEG-PLGA-based polymeric capsule as theranostic nanoplatform for active targeting atherosclerosis

Chen¹,

Sun²,

Li³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Atherosclerosis plaque is a major cause of cardiovascular diseases across the globe, which is characterized by a gradual formation of atherosclerotic plaque, hardening, and narrowing of the arteries. Nano-materials can serve as powerful delivery platforms for atherosclerosis treatment. Herein we systematically developed polymeric capsule with active targeting property encapsulating curcumin (Cur) and C-C chemokine receptor type 2 with short-interfering RNA (CCR2-siRNA) for combined treatment, which was also loaded with Gd3+ for magnatic resonance imaging (MRI) and a near-infrared fluorochrome (IR780) for fluorescence imaging (FI).Results The resulting nano-capsule exhibited a favorable hydrodynamic size and negative surface charge. More importantly, the negative charge and active-targeting peptide resulted in enhanced accumulation of nano-capsule in the established atherosclerotic plaques, thereby achieving targeted drug release. The in vitro and in vivo results indicated the effective diagnostic and therapeutic sensitivity, which could promote the development of theranostics for clinical implementation.Conclusions This study demonstrated that chemotherapy combined with gene therapy can displayed synergistic effect in atherosclerosis treatment, which possessed efficient management of atherosclerosis.

show abstract

“…Traditionally, stenting and nanoparticle (NP) technology are used to treat atherosclerosis [ 7 ]. However, both the drug-eluting stent and the bare metal stent cause restenosis and stent thrombosis to a certain extent [ 8 ]. Much of the NP technology that might be used for drug delivery utilize organic, inorganic or metallic materials that show cytotoxicity and low biocompatibility-features that need to be overcome in order for this technology to be used in the treatment of atherosclerosis.…”

Section: Introductionmentioning

confidence: 99%

Cell-derived biomimetic nanoparticles as a novel drug delivery system for atherosclerosis: predecessors and perspectives

Long

Zang

et al. 2020

Regenerative Biomaterials

View full text Add to dashboard Cite

Atherosclerosis is a key mechanism underlying the pathogenesis of cardiovascular disease, which is associated with high morbidity and mortality. In the field of precision medicine for the treatment of atherosclerosis, nanoparticle (NP)-mediated drug delivery systems have great potential, owing to their ability to release treatment locally. Cell-derived biomimetic NPs have attracted extensive attention at present due to their excellent targeting to atherosclerotic inflammatory sites, low immunogenicity and long blood circulation time. Here, we review the utility of cell-derived biomimetic NPs, including whole cells, cell membranes and extracellular vesicles, in the treatment of atherosclerosis.

show abstract

Atherosclerosis Treatment with Stimuli‐Responsive Nanoagents: Recent Advances and Future Perspectives

Cited by 67 publications

References 246 publications

Nanoerythrocyte Membrane–Enveloped ROS‐Responsive 5‐Aminolevulinic Acid Prodrug Nanostructures with Robust Atheroprotection

Nanoerythrocyte Membrane–Enveloped ROS‐Responsive 5‐Aminolevulinic Acid Prodrug Nanostructures with Robust Atheroprotection

A PEG-PLGA-based polymeric capsule as theranostic nanoplatform for active targeting atherosclerosis

Cell-derived biomimetic nanoparticles as a novel drug delivery system for atherosclerosis: predecessors and perspectives

Contact Info

Product

Resources

About